<p><?tk 4?>Rheumatoid arthritis is a long-lasting autoimmune illness that causes pain and inflammation in the joints. Conventional medications usually don’t work on inflammation, don’t get absorbed very well or have negative effects across the body when used for a long time. Ethosomes might help with problems with distribution systems. This research examines ethosome composition, flexibility, and transdermal efficacy. This makes them useful topical rheumatoid arthritis therapies. The research indicated that ethosomes demonstrated superior efficacy, enhanced safety, and a higher likelihood of application compared to alternative drug delivery systems targeting specific regions. This review provides an in-depth analysis of the mechanisms by which ethosomes interact with biologic therapies and small-molecule inhibitors in the treatment of rheumatoid arthritis. Identifying innovative therapies that effectively combat inflammation, enhance physiological responses and alter disease trajectories is of utmost significance. It is essential to obtain evidence prior to the clinical trial demonstrating their applicability in ethosomes. When considering preparation methods such as sonication, microfluidization, and both hot and cold techniques, it is crucial to prioritize scalability and consistency. Ethosomal formulations may help rheumatoid arthritis, however stability, production and regulatory approval are issues. The paper ends with some ideas for more research that could be done. Translational research connects discoveries made in the lab with real-world problems that need to be solved. This review suggests ethosomes could be exploited to develop rheumatoid arthritis&#xa0;drugs.</p> Graphical Abstract <p></p>